J&J won't pursue broader uses of Procrit

Johnson & Johnson says it's giving up its quest to expand the uses for its anemia drug Procrit, after a new clinical trial failed. Published in the New England Journal of Medicine today, the study didn't prove a decrease in red-blood-cell transfusions among critically ill patients taking Procrit.

The company had wanted to expand indications for Procrit to include all intensive-care patients with anemia, regardless of diagnosis. Currently, the drug is approved for anemic patients preparing for surgery or chemotherapy, and for those who also have HIV or kidney failure.

- read the the Wall Street Journal article on Procrit
-
see the report from Forbes

Related Articles:
New study points to danger of anemia drug. Report
FDA considers anemia drug trials on safety concerns. Report
FDA panel votes for restrictions on anemia drugs. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.